K. Yamamoto

Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

I. Nagata, Y. Kikuchi, K. Kudoh, 2000, Journal of Cancer Research and Clinical Oncology.

Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.

I. Nagata, J. Hirata, T. Kita, 2000, Japanese journal of clinical oncology.

Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer.

I. Nagata, J. Hirata, T. Kita, 1999, European journal of cancer.

Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.

I. Nagata, J. Hirata, T. Kita, 1997, European journal of cancer.

Studies on micronuclei time response and on the effects of multiple treatments of mutagens on induction of micronuclei.

K. Yamamoto, Y. Kikuchi, 1981, Mutation research.

Induction of micronuclei in mouse fetal liver after exposure in utero to N-methyl-N'-nitro-N-nitrosoguanidine.

K. Yamamoto, Y. Kikuchi, 1984, Mutation research.

A comparison of diameters of micronuclei induced by clastogens and by spindle poisons.

K. Yamamoto, Y. Kikuchi, Koichi I. Yamamoto, 1980, Mutation research.

Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients.

I. Nagata, M. Miwa, M. Takano, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Telomerase activity in gynecological tumors.

M. Sakamoto, H. Nakayama, D. Aoki, 2000, Oncology reports.

Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.

K. Shiromizu, H. Yoshikawa, T. Hirakawa, 2001, Gynecologic oncology.

Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer.

T. Goto, M. Takano, T. Kita, 2001, Human cell.